Teva Pharmaceutical Industries Limited - Product Pipeline Review - 2014

Published: Jun, 2014 | Pages: 169 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Teva Pharmaceutical Industries Limited - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Teva Pharmaceutical Industries Limited - Product Pipeline Review - 2014', provides an overview of the Teva Pharmaceutical Industries Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Teva Pharmaceutical Industries Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Teva Pharmaceutical Industries Limited including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Teva Pharmaceutical Industries Limited's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Teva Pharmaceutical Industries Limited's pipeline products

Reasons to buy

- Evaluate Teva Pharmaceutical Industries Limited's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Teva Pharmaceutical Industries Limited in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Teva Pharmaceutical Industries Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Teva Pharmaceutical Industries Limited and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Teva Pharmaceutical Industries Limited
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Teva Pharmaceutical Industries Limited and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Teva Pharmaceutical Industries Limited Snapshot 6
Teva Pharmaceutical Industries Limited Overview 6
Key Information 6
Key Facts 6
Teva Pharmaceutical Industries Limited - Research and Development Overview 7
Key Therapeutic Areas 7
Teva Pharmaceutical Industries Limited - Pipeline Review 12
Pipeline Products by Stage of Development 12
Pipeline Products - Monotherapy 13
Pipeline Products - Combination Treatment Modalities 14
Pipeline Products - Partnered Products 15
Pipeline Products - Out-Licensed Products 18
Teva Pharmaceutical Industries Limited - Pipeline Products Glance 20
Teva Pharmaceutical Industries Limited - Late Stage Pipeline Products 20
Teva Pharmaceutical Industries Limited - Clinical Stage Pipeline Products 23
Teva Pharmaceutical Industries Limited - Early Stage Pipeline Products 25
Teva Pharmaceutical Industries Limited - Unknown Stage Pipeline Products 27
Teva Pharmaceutical Industries Limited - Drug Profiles 28
(desogestrel + ethinyl estradiol) 28
balugrastim 29
laquinimod sodium 31
lipegfilgrastim 33
(nomegestrol acetate + estradiol) 34
DR-2011 36
(fluticasone propionate+salmeterol xinafoate) 37
armodafinil 38
beclomethasone dipropionate 40
bendamustine 42
custirsen sodium 44
hydrocodone bitartrate ER 47
Leukocyte Interleukin Injection 49
pridopidine 52
reslizumab 54
pagoclone 55
(levonorgestrel + ethinyl estradiol) 57
mercaptopurine DR 58
omacetaxine mepesuccinate 59
TV-1106 62
TV-1380 63
TV-45070 64
CEP-32496 65
CEP-37250 66
CEP-37440 68
CEP-9722 69
glatiramer acetate 70
irdabisant 72
rasagiline 73
XMT-1107 74
CEP-11981 76
CEP-28122 78
CEP-33779 79
CEP-37248 80
CEP-40783 81
modafinil next generation 83
NP-201 84
NP-202 85
Small Molecule-2 to Antagonize 5-HT6 for CNS 87
(immediate release opioid 1 + acetaminophen) 88
(immediate release opioid 2 + acetaminophen) 89
(Prostaglandin Agonist + Beta-Blocker) 90
AD-3 91
AD-4 92
Fixed Dose Combination-1 for HIV 93
Fixed Dose Combination-2 for HIV 94
Fixed Dose Combination-3 for HIV 95
Fixed Dose Combination-4 for HIV 96
Small Molecule to Inhibit Poly (ADP-Ribose) Polymerase 1 for Undisclosed Indication 97
Small Molecule-1 Targeting 5-HT6 for CNS Disorders 98
Drug for Dependence 99
Drug For Parkinson Disease 100
risperidone LAI 101
Teva Pharmaceutical Industries Limited - Pipeline Analysis 102
Teva Pharmaceutical Industries Limited - Pipeline Products by Target 102
Teva Pharmaceutical Industries Limited - Pipeline Products by Route of Administration 106
Teva Pharmaceutical Industries Limited - Pipeline Products by Molecule Type 108
Teva Pharmaceutical Industries Limited - Pipeline Products by Mechanism of Action 110
Teva Pharmaceutical Industries Limited - Recent Pipeline Updates 115
Teva Pharmaceutical Industries Limited - Dormant Projects 147
Teva Pharmaceutical Industries Limited - Discontinued Pipeline Products 152
Discontinued Pipeline Product Profiles 152
Teva Pharmaceutical Industries Limited - Company Statement 156
Teva Pharmaceutical Industries Limited - Locations And Subsidiaries 159
Head Office 159
Other Locations & Subsidiaries 159
Appendix 164
Methodology 164
Coverage 164
Secondary Research 164
Primary Research 164
Expert Panel Validation 164
Contact Us 165
Disclaimer 165

List of Tables
Teva Pharmaceutical Industries Limited, Key Information 10
Teva Pharmaceutical Industries Limited, Key Facts 10
Teva Pharmaceutical Industries Limited - Pipeline by Indication, 2014 12
Teva Pharmaceutical Industries Limited - Pipeline by Stage of Development, 2014 16
Teva Pharmaceutical Industries Limited - Monotherapy Products in Pipeline, 2014 17
Teva Pharmaceutical Industries Limited - Combination Treatment Modalities in Pipeline, 2014 18
Teva Pharmaceutical Industries Limited - Partnered Products in Pipeline, 2014 19
Teva Pharmaceutical Industries Limited - Partnered Products/ Combination Treatment Modalities, 2014 20
Teva Pharmaceutical Industries Limited - Out-Licensed Products in Pipeline, 2014 22
Teva Pharmaceutical Industries Limited - Out-Licensed Products/ Combination Treatment Modalities, 2014 23
Teva Pharmaceutical Industries Limited - Pre-Registration, 2014 24
Teva Pharmaceutical Industries Limited - Filing rejected/Withdrawn, 2014 25
Teva Pharmaceutical Industries Limited - Phase III, 2014 26
Teva Pharmaceutical Industries Limited - Phase II, 2014 27
Teva Pharmaceutical Industries Limited - Phase I, 2014 28
Teva Pharmaceutical Industries Limited - Preclinical, 2014 29
Teva Pharmaceutical Industries Limited - Discovery, 2014 30
Teva Pharmaceutical Industries Limited - Unknown, 2014 31
Teva Pharmaceutical Industries Limited - Pipeline by Target, 2014 106
Teva Pharmaceutical Industries Limited - Pipeline by Route of Administration, 2014 111
Teva Pharmaceutical Industries Limited - Pipeline by Molecule Type, 2014 113
Teva Pharmaceutical Industries Limited - Pipeline Products by Mechanism of Action, 2014 115
Teva Pharmaceutical Industries Limited - Recent Pipeline Updates, 2014 119
Teva Pharmaceutical Industries Limited - Dormant Developmental Projects,2014 151
Teva Pharmaceutical Industries Limited - Discontinued Pipeline Products, 2014 156
Teva Pharmaceutical Industries Limited, Other Locations 163
Teva Pharmaceutical Industries Limited, Subsidiaries 164